CS Paper Radar

iGC: Antibody Optimization via Reinforcement Learning over a Learned Somatic Hypermutation Prior

Thao Nguyen, Robert G. Alberstein, Ewa Nowara, Homa MohammadiPeyhani, Holly R. Steach, Sarah A. Robinson, Yuval Shechter, Donald W. Lee, Jason A. Vander Heiden, Franziska Seeger, Andrew Leaver-Fay, Richard Bonneau, Joshua Yao-Yu Lin

cs.LG q-bio.BM ·submitted 2026-11-03 17:55 UTC · v1

Abstract

Antibody affinity maturation is a natural optimization process in which B cells acquire mutations through somatic hypermutation (SHM), undergo selection for improved antigen binding, and iteratively evolve toward higher affinity. Computationally modeling this process requires capturing both biologically plausible mutations and antigen-specific selection. However, existing mutation models do not directly optimize binding, while affinity optimization often neglects realistic mutation trajectories. We introduce iGC (in silico Germinal Centers), a two-stage reinforcement learning (RL) framework for antigen-specific antibody optimization. Stage 1 learns an SHM mutation prior from parent-child pairs in B-cell lineage trees and adapts it to a target affinity-maturation dataset. Stage 2 initializes an RL policy from this prior and optimizes antigen binding with Kullback-Leibler (KL) regularization toward the frozen prior. To prevent reward exploitation, including repetitive high-reward substitutions and structurally tolerated framework mutations, we introduce a Reward-Tax Meta-Gradient objective. RewardNet smooths the affinity landscape, while TaxNet penalizes reward overexploitation, jointly defining a learned meta-reward for policy optimization. We evaluate iGC on mutation prediction, SHM consistency, affinity optimization, and mutation diversity. The mutation prior more than doubles the strongest baseline in mutation-site prediction. Following RL optimization, iGC maintains SHM sequence structure. It also achieves a strong exploration-exploitation balance, yielding competitive reward-diversity products across candidate-selection cutoffs. These results demonstrate that iGC integrates biologically plausible mutation generation with antigen-specific affinity selection, providing an in silico framework for iterative antibody affinity maturation.

Comment
10 pages with supplementary documents

Closest papers

Nearest neighbours by meaning across the whole index.

Multi-Objective Amortized CDRH3 Sequence Sampling Diversifies Promising Antibody Candidates

cs.CE ·2026-10-12 ·Joseph D. Viviano, Almer van der Sloot, Quentin Fournier, Robert M. Vernon, Christopher James Langmead +1 more
similarity 0.68
Abstract · 21 Figures, 14 Tables, Under review

Antibody therapeutics have transformed treatment across diverse therapeutic areas and have become central to modern medicine. While recent machine learning approaches aim to accelerate antibody discovery through structure-based design and target-affinity optimization, successful candidates must also satisfy broad developability constraints, including structural compatibility, low immunogenicity, and favorable biophysical properties, while remaining sufficiently diverse to provide sufficient coverage of design space to mitigate later-stage development failures. We introduce a preference-conditioned multi-objective generative flow network (GFN) fine-tuning pipeline for fixed-framework CDRH3 loop redesign that fine-tunes a biological sequence model against many inexpensive proxies covering backbone compatibility, sequence likelihood, immunogenicity risk, novelty, and developability liabilities. It combines up to fourteen predictive rewards in a single policy trained to sample CDRH3 loops across 623 SAbDab antibody structures, leveraging a reward reduction strategy to preserve Pareto dominance under this learned map. We also introduce a novel autoregressive span-in-filling variant of AMPLIFY-350M that serves both as a scaffold-conditioned CDRH3 generation prior and as a direct conditional likelihood scorer. We evaluated reward scores, diversity, and design quality on loops sampled on 45 held-out antibody complexes to assess structural consistency, confidence, aggregation propensity, stability, and antigen binding. Compared with the inverse-folding methods ProteinMPNN and ESM-IF, our approach produces roughly 10x more distinct acceptable candidates per design at 50% sequence identity, while holding 10% of the 14-objective Pareto front pooled across methods, trading per-sample quality for greater exploration of novel possible structures.

0.33

Elite-Weighted Supervised Fine-tuning for Goal-Directed Molecular Optimization

cs.LG ·2026-08-31 ·Shiyun Wa, Yifei Wang, Anna G. Green, Simone Sciabola, Ye Wang
benchmark similarity 0.64
Abstract

Goal-directed optimization is essential for steering molecular generators to propose candidates with desired properties. However, it is often implemented with policy-gradient reinforcement learning, which requires a generation-trajectory log-probability whose form depends on the model architecture and generation procedure. This makes an optimizer difficult to reuse across architectures and conditional generative designs. Supervised fine-tuning needs none of that machinery, but its update is driven by a fixed dataset, so the reward never enters the update. We introduce Elite-Weighted Supervised Fine-tuning (EW-SFT), which uses reward to guide elite selection of high-scoring molecules, and updates the model by its own pretraining loss on that set. Ablations show that reward information is passed primarily through elite selection, rather than through continuous weighting within the selected set. Because the update consumes only scored molecules and the model's native loss, the same rule applies across autoregressive, masked-diffusion, and discrete-flow generators, and across de novo, motif-extension, and linker-design tasks. Under a fixed budget of 3D shape alignment oracle calls on two kinase reference compounds, EW-SFT consistently outperforms the corresponding native optimizers. It further improves goal-directed optimization under a 2D similarity oracle on four held-out references and achieves comparable performance on a sample-efficiency benchmark without a trajectory-level RL formulation. These results demonstrate that EW-SFT is a unified and effective optimizer across molecular generators, design constraints, references, and oracles.

0.21

Structure-aware Reinforcement Learning for Protein Directed Evolution

cs.LG cs.AI ·2026-09-30 ·Zikun Nie, Suyuan Zhao, Yizhen Luo, Siqi Fan, Zaiqing Nie
similarity 0.63
Abstract

Protein optimization remains a longstanding goal in life sciences. Existing machine learning-assisted directed evolution (MLDE) methods primarily rely on sequence-only features, overlooking the critical spatial constraints and co-evolutionary interactions encoded in protein structures. However, directly integrating structural information remains challenging due to the scarcity of reliable mutant structures. To address these issues, we propose StructEvo, a novel structure-aware reinforcement learning framework for protein directed evolution. StructEvo employs a delta-structure fusion encoder to approximate mutant structure features via feature differences, enabling dynamic incorporation of spatial knowledge. The vast mutation space is then decomposed into manageable subspaces through a structure-aligned hierarchical action network, while a geometric constraint further stabilizes delta feature learning. Our approach outperforms prior state-of-the-art methods by 9.2% and 16.3% on two challenging optimization benchmarks, and further identifies an experimentally validated epistasis pattern in GFP, highlighting the importance of structural guidance for effective protein directed evolution.

0.31

Can agents reliably design therapeutic antibodies?

cs.LG q-bio.QM ·2026-10-31 ·Asli Alpman, Nick Bhattacharya, Aaron Solomon, Hunter Elliott
similarity 0.63
Abstract

Recent work has demonstrated agents driving protein design workflows, either through orchestration of specialized tools or direct manipulation of sequences. Yet the fidelity with which agents follow protein design instructions and the factors contributing to their effectiveness remain understudied. We examine agentic antibody design under two settings: when explicit molecular-editing instructions are provided and when agents receive only previously-scored sequences and are prompted to propose improvements. We call the first task-guided and the second black-box design. For the task-guided setting, we curate ten expert-validated affinity-improvement tasks and show that LLM judges closely reproduce programmatic evaluations of instruction following. We then study two augmentations: access to antibody-relevant tools and to previously scored design history. Tools improve instruction following (IF) and sequence space exploration while reducing optimization performance, whereas design history reduces IF but improves optimization performance at the expense of exploration. Finally, we combine taskguided and black-box design within an in silico optimization loop and show that our agentic optimizer performs comparably to an established Bayesian optimization baseline.

0.08

Learning Task-Specific Antibody Representations via Function-Aware Masking

cs.LG q-bio.BM ·2026-09-01 ·Ayan Goel, Thomas A. Walton, Amirali Aghazadeh
published similarity 0.63
Abstract · Accepted to MLCB 2026 (Oral)

Antibody-specific language models pretrained via masked language modeling (MLM) learn representations that are critical for downstream sequence design and property prediction tasks. Yet, the corruption process itself is rarely leveraged as a source of inductive bias during pretraining. While preferentially masking complementarity-determining regions (CDRs) improves binding-related predictions, antibodies possess diverse biological priors over a variety of functions. Herein, we introduce function-aware masking, a family of pretraining algorithms that align mask placement with specific functional priors (e.g., from IMGT annotations or structure predictions) to shape the learned representation space. We show that these specialist masking strategies significantly improve performance on their respective objectives, yielding up to a 14% gain on structure-related tasks and up to a 5.9x improvement on CDR-related tasks. To further improve performance across multiple functional axes, we develop hybrid masking strategies that integrate multiple priors, balancing reconstruction over binding, structural, and biophysical objectives. Our results demonstrate that informed mask placement provides a parameter-free mechanism for imposing functional inductive biases in antibody language model training.

0.31

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

cs.AI q-bio.QMcs.CEq-bio.CB ·2026-10-02 ·Hantao Lou, Jianqing Zheng, Can Yue, Meihan Zhang, Yuanchao Bao +19 more
similarity 0.62
Abstract

Discovering broadly neutralizing antibodies (bnAbs) from human natural immune repertoires remains a fundamental challenge in immunology, hindered by: the extreme rarity of bnAb, incomplete understanding of their cellular origins across pathogens, and the inability of existing computational tools to generalize across emerging viral threats. Here we present ImmuneAgent, a closed-loop AI system that integrates multimodal reasoning with continual meta-learning and wet-lab feedback to overcome these barriers. Applied to screen the natural BCR repertoires from vaccinated or infected cohorts, the system achieves a ~55% neutralization antibody discovery rate (60 of 110 cloned candidates) and a ~11% bnAb yield (12 of 110), substantially outperforming a state-of-the-art sequence-based neutralization predictor or cofolding models evaluated at the same cloning budget. Five ImmuneAgent-discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to the clinical-stage therapeutic MEDI8852. The system recovered the cellular and structural determinants of bnAb activity and identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and hydrophobic interface enrichment as a cross-viral structural signature, which generalized to unseen antigens, discovering human metapneumovirus (hMPV) cross-neutralizing and human papillomavirus (HPV)-neutralizing antibodies without antigen-specific sorting. These results validate that ImmuneAgent is a generalizable framework for rapid therapeutic antibody discovery against emerging viral threats.

0.20

Probabilistic Steering of Generative Priors for Lab-in-the-Loop Antibody Optimization

cs.LG ·2026-11-02 ·Anisha Parsan, Sebastian Ober, Calvin McCarter, Nick Bhattacharya, Hunter Elliott
top venue similarity 0.60
Abstract · Accepted to NeurIPS `26 GEM and NeurIPS `26 AI4DD

Therapeutic antibody development is often framed as comprising two discrete stages: initial discovery of novel binders followed by iterative optimization to refine these hits into therapeutic-grade molecules. Models and methods often reflect these stages, with generative structure models applied to discovery and probabilistic black-box optimization methods applied to refinement. Here we propose to unify these stages by smoothly transitioning a generative discovery model into iterative optimization, allowing the handoff between the structure-based prior and supervision from wet lab data to be guided by the posterior uncertainty of a probabilistic surrogate. We show that this yields improvements in optimization efficiency in the low-N regime, as well as improved diversity amongst the optimized molecules.

0.36

MFG: Multi-turn Feedback Guided Molecular Optimization

cs.AI cs.LGq-bio.QM ·2026-10-13 ·Trieu Nguyen, Frazier N. Baker, Ruoxi Gao, Daniel Adu-Ampratwum, Xia Ning
similarity 0.60
Abstract

Multi-objective molecular optimization is a critical process in drug discovery that aims to modify a given molecule to simultaneously improve multiple properties while maintaining a similar overall structure. This process often requires iterative modifications guided by computational or experimental feedback. Recent large language model (LLM)-based methods have begun to explore this iterative approach; however, these methods are not explicitly trained to leverage such feedback, while existing approaches primarily focus on single-turn molecular optimization. To address this gap, we introduce Multi-turn Feedback Guided (MFG) molecular optimization, a reinforcement learning framework that trains an LLM to progressively optimize molecules using feedback from previous turns. MFG introduces a feedback vector capturing both property improvements and source molecule similarity, alongside a feedback-aligned reward function that promotes progressive improvement across turns. We apply MFG over $\text{GeLLM}^{3}\text{O}$, a state-of-the-art LLM model for multi-objective molecular optimization, evaluate $\text{GeLLM}^{3}\text{O-MFG}$ on ten multi-objective molecular optimization tasks. The results demonstrate that $\text{GeLLM}^{3}\text{O-MFG}$ achieves the highest average similarity-constrained success rate ($81.50%$), outperforming the base model $\text{GeLLM}^{3}\text{O}$ ($70.81%$).

0.17